We are live on ! Find out more
ACM

Aquilo Capital Management Portfolio holdings

AUM $55.8M
1-Year Est. Return 41.76%
This Fund
S&P 500
This Quarter Est. Return
+3.56%
1 Year Est. Return
-41.76%
3 Year Est. Return
-6.84%
5 Year Est. Return
+20.73%
10 Year Est. Return
–
AUM
$551M
AUM Growth
+$166M
Cap. Flow
+$55.6M
Cap. Flow %
10.1%
Top 10 Hldgs %
91.73%
Holding
17
New
2
Increased
11
Reduced
–
Closed
3

Top Buys

Rank Stock Value
1
ARVN icon
Arvinas
ARVN
+$31.3M
2
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$17.8M
3
SPRO icon
Spero Therapeutics
SPRO
+$11.8M
4
RGNX icon
Regenxbio
RGNX
+$8.77M
5
BPMC
Blueprint Medicines
BPMC
+$6.81M

Top Sells

Rank Stock Value
1
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
+$23.6M
2
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$9.88M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$9.81M

Sector Composition

Rank Sector Weight
1 Healthcare 77.17%
2 Miscellaneous 22.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$126M 22.83%
+1,000,000
New +$129M
SPRO icon
2
Spero Therapeutics
SPRO
$72.8M
$84M 15.26%
4,563,688
+734,479
+19% +$11.8M
BPMC
3
DELISTED
Blueprint Medicines
BPMC
$53.6M 9.74%
521,673
+73,161
+16% +$6.81M
DRNA
4
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$49.5M 8.99%
2,456,595
+643,203
+35% +$17.8M
QURE icon
5
uniQure
QURE
$2.66B
$42.2M 7.67%
1,319,513
+162,000
+14% +$4.94M
RGNX icon
6
Regenxbio
RGNX
$478M
$35.2M 6.39%
839,139
+243,695
+41% +$8.77M
ARWR icon
7
Arrowhead Research
ARWR
$9.33B
$33M 5.99%
527,926
+95,000
+22% +$6.15M
FDMT icon
8
4D Molecular Therapeutics
FDMT
$813M
$29.7M 5.39%
1,099,944
+154,562
+16% +$4.41M
ARVN icon
9
Arvinas
ARVN
$509M
$29.1M 5.29%
+354,711
New +$31.3M
DNTH icon
10
Dianthus Therapeutics
DNTH
$5.07B
$23M 4.17%
197,193
+29,244
+17% +$3.41M
AMYT
11
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$16.7M 3.04%
1,390,000
+250,000
+22% +$2.82M
PVLA
12
Palvella Therapeutics
PVLA
$2.1B
$16.5M 3%
39,957
– –
ARGX icon
13
argenx
ARGX
$60.2B
$6.7M 1.22%
22,200
+1,000
+5% +$317K
GMAB icon
14
Genmab
GMAB
$21.4B
$5.57M 1.01%
127,500
+7,500
+6% +$337K
LKFT
15
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.99B
– –
-142,340
Closed -$9.81M
NGM
16
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
– –
-1,194,237
Closed -$23.6M
HARP
17
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
– –
-71,267
Closed -$9.88M

Similar funds

VCM
VeriStar Capital Management New York $54.7M AUM 2.08% 1-Year Est. Return
YEPV
Yorktown Energy Partners VIII New York $52.9M AUM 30% 1-Year Est. Return
HWP
Heritage Wealth Partners Dublin, Ohio $65.6M AUM 16.69% 1-Year Est. Return
GIS
Grayhawk Investment Strategies Calgary, Alberta, Canada $43.9M AUM 6.23% 1-Year Est. Return
AA
AlphaQ Advisors Winter Park, Florida $41.7M AUM 12.96% 1-Year Est. Return
PGIM
Pacific Global Investment Management Glendale, California $70.7M AUM 14.46% 1-Year Est. Return
RGMC
Revolution Growth Management Company Washington, District of Columbia $70.8M AUM 20.1% 1-Year Est. Return
PAM
Pamalican Asset Management Hong Kong $75.4M AUM

Aquilo Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Aquilo Capital Management held 17 positions worth $551M, up 43% from $385M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Aquilo Capital Management deployed $55.6M of net new capital in Q3 2021, opening 2 new positions and adding to 11 existing holdings. Its largest new stake was Arvinas: 354,711 shares worth $29.1M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the most notable exit was NGM Biopharmaceuticals, Inc. Common Stock, an estimated $23.6M sold.

  • Aquilo Capital Management's largest Q3 2021 buy was Arvinas: 354,711 shares worth $29.1M.
  • Aquilo Capital Management added most to Dicerna Pharmaceuticals, Inc. in Q3 2021, an estimated $17.8M increase.
  • Aquilo Capital Management fully exited NGM Biopharmaceuticals, Inc. Common Stock in Q3 2021, selling an estimated $23.6M.
  • Aquilo Capital Management's ten largest holdings make up 92% of its $551M portfolio in Q3 2021.
  • Aquilo Capital Management opened 2 new positions and closed 3 in Q3 2021.
  • Aquilo Capital Management's portfolio value rose 43% quarter-over-quarter to $551M.

Based on Aquilo Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.